ArticleJournal of proteome research2015
Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue.
Article in Journal of proteome research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 73 citations in OpenAlex.
- Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.Molecules (Basel, Switzerland) · 2019Trial
- Mannose supports lung cancer metabolism during glycolytic limitation.EMBO reports · 2026Article
- The receptor landscape of influenza A viruses.Journal of virology · 2026Review
- Glycan Fingerprint of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2026Article
- Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab.Oncology letters · 2026Article
- A comprehensive landscape of human organ N-glycoproteome.Nature communications · 2026Article
- CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function.bioRxiv : the preprint server for biology · 2026Article
- N-glycans in lung tissue specimens: a prospective target for enhanced cancer diagnosis and prognosis.Journal of translational medicine · 2025Article
- Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.International journal of molecular sciences · 2025Article
- Integration of RNAseq transcriptomics andChemical science · 2025Article
- Serum N-Glycomics with Nano-LC-QToF LC-MS/MS Reveals N-Glycan Biomarkers for Glioblastoma, Meningioma, and High-Grade Meningioma.Journal of proteome research · 2025Article
- Glycosylation in Cancer.Handbook of experimental pharmacology · 2025Review
- Recent advances in N-glycan biomarker discovery among human diseases.Acta biochimica et biophysica Sinica · 2024Review
- The effects of immortalization on the N-glycome and proteome of CDK4-transformed lung cancer cells.Glycobiology · 2024Article
- Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations.Journal of oncology · 2024Article
- Article
- Quantitative analysis of fucosylated glycoproteins by immobilized lectin-affinity fluorescent labeling.RSC advances · 2023Article
- Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer.Translational lung cancer research · 2022Article
- Article
- Quantitative clinical glycomics strategies: A guide for selecting the best analysis approach.Mass spectrometry reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
To decrease the mortality of lung cancer, better screening and diagnostic tools as well as treatment options are needed. Protein glycosylation is one of the major post-translational modifications that is altered in cancer, but it is not exactly clear which glycan structures are affected. A better understanding of the glycan structures that are differentially regulated in lung tumor tissue is highly desirable and will allow us to gain greater insight into the underlying biological mechanisms of aberrant glycosylation in lung cancer. Here, we assess differential glycosylation patterns of lung tumor tissue and nonmalignant tissue at the level of individual glycan structures using nLC-chip-TOF-MS. Using tissue samples from 42 lung adenocarcinoma patients, 29 differentially expressed (FDR < 0.05) glycan structures were identified. The levels of several oligomannose type glycans were upregulated in tumor tissue. Furthermore, levels of fully galactosylated glycans, some of which were of the hybrid type and mostly without fucose, were decreased in cancerous tissue, whereas levels of non- or low-galactosylated glycans mostly with fucose were increased. To further assess the regulation of the altered glycosylation, the glycomics data was compared to publicly available gene expression data from lung adenocarcinoma tissue compared to nonmalignant lung tissue. The results are consistent with the possibility that the observed N-glycan changes have their origin in differentially expressed glycosyltransferases. These results will be used as a starting point for the further development of clinical glycan applications in the fields of imaging, drug targeting, and biomarkers for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.